New Innovative Daily Disposable Contact Lens Designed to Provide Astigmatic Patients
Consistently Clear Vision and Comfort Throughout the Day
LAVAL, Quebec, March 15, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") wholly owned subsidiary Bausch + Lomb, a leading global eye health company, today announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses. Approximately 73.2 million people in the U.S. are astigmatic, but only 8.8 million people are currently wearing toric contact lenses.1 Biotrue® ONEday for Astigmatism helps eye care practitioners capture this astigmatic opportunity by offering patients the convenience of a daily disposable contact lens with the innovation of an evolved peri-ballast design for stability and a unique dehydration barrier to help the lens maintain 98% of its moisture for up to 16 hours.1
Biotrue® ONEday features a bio-inspired design that starts and ends the day with more moisture than the leading daily disposable contact lenses.1 The advanced technology of Biotrue® ONEday for Astigmatism provides today's patients with consistently clear vision and comfort throughout the day.1
"Biotrue® ONEday for Astigmatism contact lenses were designed to provide eye care practitioners an innovation that meets the lifestyle demands of their astigmatic patients today," said Joseph C. Papa, Chairman and CEO of Valeant. "The introduction of this lens also completes the Biotrue® ONEday portfolio, joining Biotrue® ONEday and Biotrue® ONEday for Presbyopia contact lenses in
Bausch + Lomb's U.S. Vision Care portfolio."
As part of the lens development process, Bausch + Lomb scientists assessed blink patterns across a wide range of patients to design a lens that works with the eye for stable, clear vision.1 Similar to Biotrue® ONEday and Biotrue® ONEday for Presbyopia, Biotrue® ONEday for Astigmatism utilizes Surface Active TechnologyTM, which provides a unique dehydration barrier helping the lens maintain 98% of its moisture for up to 16 hours.1
For more information on the new Biotrue® ONEday for Astigmatism contact lenses, visit the Newsroom section at www.bausch.com.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
- Data on file. Bausch & Lomb Incorporated. Rochester, NY; 2007, 2011, 2012, 2016.
877-281-6642 (toll free)
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
SOURCE Valeant Pharmaceuticals International, Inc.